Mode
Text Size
Log in / Sign up
N/A Completed N=5 Device Feasibility

GRX With ReMOTE: First in Human in India

Source: ClinicalTrials.gov NCT03705481 ↗
Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Jan 2020
Primary outcomePrimary: Device Technical Success — 5 Participants

Summary

To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.

Outcome Measures

OutcomeResultp-value
PRIMARY
Device Technical Success
5
PRIMARY
In-hospital MACE
SECONDARY
Clinical Procedural Success
5
SECONDARY
All Serious Adverse Events

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years;
  • Patients with coronary artery disease with clinical indication for PCI;
  • Patient deemed appropriate for robotic-assisted PCI; and
  • The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Angiographic Inclusion:

  • Study lesion is a single de novo native coronary artery lesion (i.e. a coronary lesion not previously treated).
  • The lesion reference vessel diameter is between 2.50 mm and 4.0 mm by visual estimate.
  • Study lesion length less or equal to 20 mm by visual estimate.
  • The study lesion length can be treated with one stent. The stent should be able to cover the whole length of the lesion with at least 2 mm of normal segments on proximal and distal edges of the lesion.
  • Study lesion diameter showing significant stenosis of at least 50% by visual estimate.

Exclusion Criteria

  • Failure/inability/unwillingness to provide informed consent; or
  • The investigator determines that the patient or the coronary anatomy is not suitable for robotic-assisted PCI.

Angiographic Exclusion:

  • Target lesion that cannot be fully covered by a single stent.
  • Subject requires treatment of multiple lesions
  • Any previous stent placement within 5 mm (proximal or distal) of the target lesion
  • The study lesion requires planned treatment with DCA, laser, rotational atherectomy, or any device except for balloon dilatation prior to stent placement
  • The study vessel has evidence of intraluminal thrombus or moderate to severe tortuosity (> 90°) proximal to the target lesion
  • The study lesion has any of the following characteristics:
  • Total occlusion
  • Within 2mm of a side branch > 2.0 mm vessel diameter
  • Not ostial in location
  • Is located at ≥ 45° bend in the vessel
  • Is severely tortuous
  • Is severely calcified
  • Severe calcification at the part of the vessel proximal to target lesion
  • Target lesion that is located in a native vessel distal to an anastomosis with a saphenous vein graft or a left/right internal mammary artery (LIMA/RIMA) bypass and is approached through the by-pass graft
  • Unprotected left main coronary artery disease (an obstruction greater than 50% diameter stenosis in the left main coronary artery)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03705481). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search